THYMOGLOBULIN Side Effects

7039288-X | Aplastic Anaemia, Disease Progression, Histiocytosis Haematophagic, No Therapeutic Response, Pneumonia, White Blood Cell Count Decreased
on Sep 21, 2010 Female patient from JAPAN , 71 years of age, weighting 141.1 lb, was diagnosed with aplastic anaemia and was treated with Thymoglobulin (View Usage). Patient experienced the following unwanted or unexpected effects: aplastic anaemia, disease progression, histiocytosis haematophagic, no therapeutic response, pneumonia (What is pneumonia?), white blood cell count decreased. Thymoglobulin dosage: 3.5 Mg/kg, Qd, Intravenous. During the same period patient was treated with CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), ITRACONAZOLE (View Itraconazole Review and Itraconazole Label ), SULFAMETHOXAZOLE W (SULFAMETHOXAZOLE, TRIMETHOPRIM) (View Sulfamethoxazole W (sulfamethoxazole, Trimethoprim) Review and Sulfamethoxazole W (sulfamethoxazole, Trimethoprim) Label ), CEFEPIME (View Cefepime Review and Cefepime Label ), FILGRASTIM (FILGRASTIM) (View Filgrastim (filgrastim) Review and Filgrastim (filgrastim) Label ).

7028007-9 |
Patient was taking Thymoglobulin (View Usage). on Aug 10, 2010 from JAPAN Additional patient health information: Female patient , 17 years of age, weighting 110.2 lb, was diagnosed with bone marrow conditioning regimen and. Thymoglobulin dosage: 1 Mg/kg, Qd, Intravenous.

7028006-7 | Bacterial Sepsis, Cholangitis, Cytomegalovirus Infection, Escherichia Sepsis, Histiocytosis Haematophagic, Oesophageal Candidiasis, Oesophagitis Haemorrhagic, Oral Candidiasis, Supraventricular Tachycardia
Adverse event was reported on Aug 10, 2010 by a Female patient taking Thymoglobulin (View Usage) (Dosage: 2.5 Mg, Once, Intravenous; 147.5 Mg, Once, Intravenous; 150 Mg, Qd, Intravenous) was diagnosed with aplastic anaemia and. Location: JAPAN , 68 years of age, weighting 103.6 lb, After Thymoglobulin was administered, patient had the following side effects: bacterial sepsis, cholangitis, cytomegalovirus infection (What is cytomegalovirus infection?), escherichia sepsis, histiocytosis haematophagic, oesophageal candidiasis, oesophagitis haemorrhagic, oral candidiasis, supraventricular tachycardia. During the same period patient was treated with CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), FILGRASTIM (FILGRASTIM) (View Filgrastim (filgrastim) Review and Filgrastim (filgrastim) Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ). Patient was hospitalized.

7028000-6 | Concomitant Disease Aggravated, Hepatitis B
on Aug 10, 2010 Male patient from JAPAN , 48 years of age, weighting 132.3 lb, was diagnosed with acute graft versus host disease and was treated with Thymoglobulin (View Usage). Patient experienced the following unwanted or unexpected effects: concomitant disease aggravated, hepatitis b (What is hepatitis b?). Thymoglobulin dosage: 50 Mg, Qd, Intravenous.


7027997-8 | Acute Myeloid Leukaemia, Malignant Neoplasm Progression
on Aug 10, 2010 Female patient from JAPAN , 50 years of age, weighting 99.21 lb, was diagnosed with bone marrow conditioning regimen and was treated with Thymoglobulin (View Usage). Patient had the following side effects: acute myeloid leukaemia, malignant neoplasm progression. Thymoglobulin dosage: 1 Mg/kg, Qd, Intravenous. During the same period patient was treated with FLUDARA (View Fludara Review and Fludara Label ), MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ).

7027994-2 | Acute Lymphocytic Leukaemia, Malignant Neoplasm Progression
Patient was taking Thymoglobulin (View Usage). After Thymoglobulin was administered, patient had the following side effects: acute lymphocytic leukaemia, malignant neoplasm progression on Aug 10, 2010 from JAPAN Additional patient health information: Female patient , 24 years of age, weighting 114.6 lb, was diagnosed with bone marrow conditioning regimen and. Thymoglobulin dosage: 1 Mg/kg, Qd, Intravenous.

7027993-0 | Acute Graft Versus Host Disease, Disease Progression
Adverse event was reported on Aug 10, 2010 by a Male patient taking Thymoglobulin (View Usage) (Dosage: 0.5 Mg/kg, Once, Intravenous; 2 Mg/kg, Once, Intravenous; 1 Mg/kg, Qd, Intravenous) was diagnosed with acute graft versus host disease, bone marrow conditioning regimen and. Location: JAPAN , 28 years of age, weighting 121.3 lb, Patient experienced the following unwanted or unexpected effects: acute graft versus host disease, disease progression.

7027960-7 | Diffuse Large B-cell Lymphoma, Disease Progression
on Aug 10, 2010 Male patient from JAPAN , 52 years of age, weighting 114.6 lb, was diagnosed with bone marrow conditioning regimen and was treated with Thymoglobulin (View Usage). Patient had the following side effects: diffuse large b-cell lymphoma, disease progression. Thymoglobulin dosage: 1 Mg/kg, Qd, Intravenous. During the same period patient was treated with FLUDARA (View Fludara Review and Fludara Label ), MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

7027928-0 | Graft Versus Host Disease
on Aug 10, 2010 Male patient from JAPAN , 65 years of age, weighting 110.2 lb, was diagnosed with acute graft versus host disease and was treated with Thymoglobulin (View Usage). After Thymoglobulin was administered, patient had the following side effects: graft versus host disease. Thymoglobulin dosage: 0.5 Mg/kg, Once, Intravenous.

7027927-9 | Acute Myeloid Leukaemia, Malignant Neoplasm Progression, Stem Cell Transplant, Thrombotic Microangiopathy
Patient was taking Thymoglobulin (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, malignant neoplasm progression, stem cell transplant, thrombotic microangiopathy on Aug 10, 2010 from JAPAN Additional patient health information: Female patient , 48 years of age, weighting 88.18 lb, was diagnosed with bone marrow conditioning regimen and. Thymoglobulin dosage: 1 Mg/kg, Qd, Intravenous. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ).

7027916-4 | Acute Graft Versus Host Disease, Acute Myeloid Leukaemia, Malignant Neoplasm Progression
Adverse event was reported on Aug 10, 2010 by a Male patient taking Thymoglobulin (View Usage) (Dosage: 25 Mg, Qd) was diagnosed with acute graft versus host disease, stem cell transplant and. Location: JAPAN , 62 years of age, weighting 132.3 lb, Patient had the following side effects: acute graft versus host disease, acute myeloid leukaemia, malignant neoplasm progression. During the same period patient was treated with TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ).

7027915-2 | Graft Versus Host Disease, Stem Cell Transplant
on Aug 10, 2010 Female patient from JAPAN , 53 years of age, weighting 101.4 lb, was diagnosed with bone marrow conditioning regimen and was treated with Thymoglobulin (View Usage). After Thymoglobulin was administered, patient had the following side effects: graft versus host disease, stem cell transplant. Thymoglobulin dosage: 1 Mg/kg, Qd, Intravenous. During the same period patient was treated with FLUDARA (View Fludara Review and Fludara Label ), MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ).

7027795-5 | Acute Graft Versus Host Disease, Malignant Neoplasm Progression, Renal Failure
on Aug 10, 2010 Female patient from JAPAN , 62 years of age, weighting 88.18 lb, was diagnosed with acute graft versus host disease, stem cell transplant and was treated with Thymoglobulin (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease, malignant neoplasm progression, renal failure. Thymoglobulin dosage: Intravenous ; 1 Mg/kg, Qd, Intravenous. During the same period patient was treated with FLUDARA (View Fludara Review and Fludara Label ), MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

7027779-7 | Acute Lymphocytic Leukaemia, Malignant Neoplasm Progression, Stem Cell Transplant
Patient was taking Thymoglobulin (View Usage). Patient had the following side effects: acute lymphocytic leukaemia, malignant neoplasm progression, stem cell transplant on Aug 10, 2010 from JAPAN Additional patient health information: Female patient , 18 years of age, weighting 110.2 lb, was diagnosed with bone marrow conditioning regimen and. Thymoglobulin dosage: 1 Mg/kg, Qd, Intravenous ; 1 Mg/kg, Qd, Intravenous. During the same period patient was treated with FLUDARA (View Fludara Review and Fludara Label ), THIOTEPA (View Thiotepa Review and Thiotepa Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ).

7027778-5 | Cerebral Haemorrhage, Engraft Failure, Infection In An Immunocompromised Host, Pseudomonal Sepsis, Surgical Procedure Repeated
Adverse event was reported on Aug 04, 2010 by a Male patient taking Thymoglobulin (View Usage) (Dosage: 151.5 Mg, Qd, Intravenous) was diagnosed with stem cell transplant and. Location: JAPAN , 60 years of age, weighting 149.9 lb, After Thymoglobulin was administered, patient had the following side effects: cerebral haemorrhage, engraft failure, infection in an immunocompromised host, pseudomonal sepsis, surgical procedure repeated. During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), BUSULFAN (BUSULFAN) (View Busulfan (busulfan) Review and Busulfan (busulfan) Label ), MICAFUNGIN SODIUM (MICAFUNGIN SODIUM) (View Micafungin Sodium (micafungin Sodium) Review and Micafungin Sodium (micafungin Sodium) Label ), LINEZOLID (View Linezolid Review and Linezolid Label ), RIFAMPICIN (View Rifampicin Review and Rifampicin Label ), DEFERASIROX (DEFERASIROX) (View Deferasirox (deferasirox) Review and Deferasirox (deferasirox) Label ), CEFEPIME HYDROCHLORIDE (View Cefepime Hydrochloride Review and Cefepime Hydrochloride Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ). Patient was hospitalized.

7027774-8 | Blood Bilirubin Increased, Blood Creatinine Increased, Blood Potassium Increased, Bronchopulmonary Aspergillosis, Condition Aggravated, Hypertension
on Aug 25, 2010 Male patient from JAPAN , 60 years of age, weighting 132.3 lb, was diagnosed with aplastic anaemia and was treated with Thymoglobulin (View Usage). Patient experienced the following unwanted or unexpected effects: blood bilirubin increased, blood creatinine increased, blood potassium increased, bronchopulmonary aspergillosis, condition aggravated, hypertension. Thymoglobulin dosage: 200 Mg, Qd, Intravenous. During the same period patient was treated with PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), SULFAMETOXAZOL MED TRIMETOPRIM (SULFAMETOXAZOLE, TRIMETHOPRIM) (View Sulfametoxazol Med Trimetoprim (sulfametoxazole, Trimethoprim) Review and Sulfametoxazol Med Trimetoprim (sulfametoxazole, Trimethoprim) Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), ALLOPURINOL (View Allopurinol Review and Allopurinol Label ), RABEPRAZOLE SODIUM (View Rabeprazole Sodium Review and Rabeprazole Sodium Label ). Patient was hospitalized.

7027771-2 | Acute Abdomen, Diverticulitis, Dysphagia, Impaired Healing, Large Intestine Perforation, Nausea, Neuroendocrine Tumour, Peritonitis, Polyneuropathy
on Aug 16, 2010 Male patient from GERMANY , 69 years of age, weighting 207.2 lb, was diagnosed with renal transplant and was treated with Thymoglobulin (View Usage). Patient had the following side effects: acute abdomen, diverticulitis, dysphagia, impaired healing, large intestine perforation, nausea (What is nausea?), neuroendocrine tumour, peritonitis, polyneuropathy. Thymoglobulin dosage: 135 Mg, Intravenous. During the same period patient was treated with PROGRAF (View Prograf Review and Prograf Label ), CELLCEPT (View Cellcept Review and Cellcept Label ), DECALFIN H (DECALFIN H) (View Decalfin H (decalfin H) Review and Decalfin H (decalfin H) Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), BISOPROLOL FUMARATE (View Bisoprolol Fumarate Review and Bisoprolol Fumarate Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ). Patient was hospitalized.

7022400-6 | Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease, Premature Menopause
Patient was taking Thymoglobulin (View Usage). After Thymoglobulin was administered, patient had the following side effects: acute graft versus host disease, chronic graft versus host disease, premature menopause on Sep 28, 2010 from FRANCE Additional patient health information: Female patient , 23 years of age, was diagnosed with bone marrow conditioning regimen and. Thymoglobulin dosage: 15 Mg/kg, Unk. During the same period patient was treated with BUSULFAN (12.8 Mg/kg, Unk) (View Busulfan Review and Busulfan Label ), CYCLOPHOSPHAMIDE (200 Mg/kg, Unk) (View Cyclophosphamide Review and Cyclophosphamide Label ).

7022332-3 | Cellulitis, Engraft Failure, Escherichia Sepsis, Stenotrophomonas Sepsis, Therapeutic Response Decreased
Adverse event was reported on Sep 22, 2010 by a Female patient taking Thymoglobulin (View Usage) (Dosage: ) was diagnosed with aplastic anaemia, bone marrow conditioning regimen, immunosuppression, prophylaxis against graft versus host disease and. Location: JAPAN , 58 years of age, Patient experienced the following unwanted or unexpected effects: cellulitis (What is cellulitis?), engraft failure, escherichia sepsis, stenotrophomonas sepsis, therapeutic response decreased. During the same period patient was treated with FLUDARABINE (25 Mg/m2, Qd) (View Fludarabine Review and Fludarabine Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), CYCLOPHOSPHAMIDE (750 Mg/m2, Unk) (View Cyclophosphamide Review and Cyclophosphamide Label ).

7021900-2 | Idiopathic Thrombocytopenic Purpura
on Sep 22, 2010 Female patient from UNITED STATES , weighting 143.3 lb, was diagnosed with prophylaxis against transplant rejection, immunosuppression, anaemia and was treated with Thymoglobulin (View Usage). Patient had the following side effects: idiopathic thrombocytopenic purpura. Thymoglobulin dosage: 125 Mg, Once. During the same period patient was treated with BASILIXIMAB (Unk) (View Basiliximab Review and Basiliximab Label ), METHYLPREDNISONE PREDNISONE (400 Mg, Once) (View Methylprednisone Prednisone Review and Methylprednisone Prednisone Label ), MYCOPHENOLATE MOFETIL (1000 Mg, Q12hr) (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), DARBEPOETIN ALFA (100 Mg, Once) (View Darbepoetin Alfa Review and Darbepoetin Alfa Label ). Patient was hospitalized.

7020560-4 | Malacoplakia Gastrointestinal, Transplant Rejection
on Sep 27, 2010 Male patient from UNITED STATES , 45 years of age, was diagnosed with prophylaxis against transplant rejection, immunosuppression and was treated with Thymoglobulin (View Usage). After Thymoglobulin was administered, patient had the following side effects: malacoplakia gastrointestinal, transplant rejection. Thymoglobulin dosage: Unk. During the same period patient was treated with TACROLIMUS (Unk) (View Tacrolimus Review and Tacrolimus Label ), MYCOPHENOLATE MOFETIL (Unk) (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), MYCOPHENOLIC ACID (View Mycophenolic Acid Review and Mycophenolic Acid Label ).

7020087-X | Epstein-barr Virus Infection, Guillain-barre Syndrome
Patient was taking Thymoglobulin (View Usage). Patient experienced the following unwanted or unexpected effects: epstein-barr virus infection, guillain-barre syndrome (What is guillain-barre syndrome?) on Sep 21, 2010 from ITALY Additional patient health information: Female patient , 51 years of age, was diagnosed with prophylaxis against graft versus host disease, bone marrow conditioning regimen, antiviral prophylaxis and. Thymoglobulin dosage: . During the same period patient was treated with CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), TIOTHEPA (View Tiothepa Review and Tiothepa Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), ACYCLOVIR SODIUM (View Acyclovir Sodium Review and Acyclovir Sodium Label ).

7018585-8 | Enterococcal Sepsis, Escherichia Sepsis, Renal Failure Acute, Therapeutic Response Decreased
Adverse event was reported on Sep 22, 2010 by a Male patient taking Thymoglobulin (View Usage) (Dosage: 275 Mg, Qd) was diagnosed with aplastic anaemia, infection prophylaxis and. Location: JAPAN , weighting 163.1 lb, Patient had the following side effects: enterococcal sepsis, escherichia sepsis, renal failure acute, therapeutic response decreased. During the same period patient was treated with CYCLOSPORINE (Unk) (View Cyclosporine Review and Cyclosporine Label ), METHYLPREDNISOLONE SODIUM SUCCINATE (Unk) (View Methylprednisolone Sodium Succinate Review and Methylprednisolone Sodium Succinate Label ), NEUPOGEN (Unk) (View Neupogen Review and Neupogen Label ), CEFOZOPRAN HYDROCHLORIDE (Unk) (View Cefozopran Hydrochloride Review and Cefozopran Hydrochloride Label ), PREDNISOLONE SODIUM SUCCINATE INJ (Unk) (View Prednisolone Sodium Succinate Inj Review and Prednisolone Sodium Succinate Inj Label ), TEICOPLANIN (Unk) (View Teicoplanin Review and Teicoplanin Label ), BIAPENEM (Unk) (View Biapenem Review and Biapenem Label ).

7017841-7 | Calciphylaxis, Cytokine Release Syndrome, Hyperparathyroidism Secondary, Renal Tubular Necrosis, Staphylococcal Infection
on Sep 24, 2010 Male patient from UNITED STATES , 43 years of age, was diagnosed with prophylaxis against transplant rejection and was treated with Thymoglobulin (View Usage). After Thymoglobulin was administered, patient had the following side effects: calciphylaxis, cytokine release syndrome, hyperparathyroidism secondary, renal tubular necrosis, staphylococcal infection (What is staphylococcal infection?). Thymoglobulin dosage: . During the same period patient was treated with HAEMODIALYSIS (View Haemodialysis Review and Haemodialysis Label ), CINACALCET (30 Mg, Qd) (View Cinacalcet Review and Cinacalcet Label ).

7017608-X | Pneumatosis Intestinalis
on Sep 22, 2010 Female patient from UNITED STATES , child 2 years of age, weighting 25.79 lb, was diagnosed with prophylaxis against transplant rejection, immunosuppression and was treated with Thymoglobulin (View Usage). Patient experienced the following unwanted or unexpected effects: pneumatosis intestinalis. Thymoglobulin dosage: 12 Mg, Qd. During the same period patient was treated with PROGRAF (View Prograf Review and Prograf Label ), CELLCEPT (View Cellcept Review and Cellcept Label ), PREDNISONE (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

7017601-7 | Cardiac Failure
Patient was taking Thymoglobulin (View Usage). Patient had the following side effects: cardiac failure on Sep 22, 2010 from JAPAN Additional patient health information: Female patient , 77 years of age, was diagnosed with aplastic anaemia and. Thymoglobulin dosage: 3.3 Mg/kg, Qd.

7014562-1 | Graft Loss, Hyperglycaemia, Pancreas Transplant Rejection
Adverse event was reported on Sep 23, 2010 by a Male patient taking Thymoglobulin (View Usage) (Dosage: 70 Mg, Qd) was diagnosed with prophylaxis against transplant rejection, immunosuppression and. Location: UNITED STATES , weighting 152.1 lb, After Thymoglobulin was administered, patient had the following side effects: graft loss, hyperglycaemia, pancreas transplant rejection. During the same period patient was treated with DACLIZUMAB (View Daclizumab Review and Daclizumab Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CORTICOSTEROIDS (View Corticosteroids Review and Corticosteroids Label ), CARDURA (2 Mg, Qd) (View Cardura Review and Cardura Label ), NORVASC (10 Mg, Qd) (View Norvasc Review and Norvasc Label ), VASOTEC (20 Mg, Qd) (View Vasotec Review and Vasotec Label ). Patient was hospitalized.

7014520-7 | Haematopoietic Neoplasm
on Sep 21, 2010 Male patient from GERMANY , 67 years of age, was diagnosed with bone marrow conditioning regimen and was treated with Thymoglobulin (View Usage). Patient experienced the following unwanted or unexpected effects: haematopoietic neoplasm. Thymoglobulin dosage: Unk Unk, Unk. During the same period patient was treated with FLUDARABINE (Unk Unk, Unk) (View Fludarabine Review and Fludarabine Label ), CYCLOPHOSPHAMIDE (Unk Unk, Unk) (View Cyclophosphamide Review and Cyclophosphamide Label ), BUSULFAN (Unk Unk, Unk) (View Busulfan Review and Busulfan Label ).

7014516-5 | Chronic Graft Versus Host Disease
on Sep 21, 2010 Male patient from GERMANY , 64 years of age, was diagnosed with bone marrow conditioning regimen and was treated with Thymoglobulin (View Usage). Patient had the following side effects: chronic graft versus host disease. Thymoglobulin dosage: Unk Unk, Unk. During the same period patient was treated with FLUDARABINE (Unk Unk, Unk) (View Fludarabine Review and Fludarabine Label ), CYCLOPHOSPHAMIDE (Unk Unk, Unk) (View Cyclophosphamide Review and Cyclophosphamide Label ), BUSULFAN (Unk Unk, Unk) (View Busulfan Review and Busulfan Label ).

7013488-7 | Oedema, Protein Urine Present
Patient was taking Thymoglobulin (View Usage). After Thymoglobulin was administered, patient had the following side effects: oedema, protein urine present on Sep 21, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 200.0 lb, was diagnosed with prophylaxis against transplant rejection and. Thymoglobulin dosage: 100 Mg, Qd. During the same period patient was treated with SOLU MEDROL (View Solu-medrol Review and Solu-medrol Label ), PRILOSEC (View Prilosec Review and Prilosec Label ), NORVASC (View Norvasc Review and Norvasc Label ), LIPITOR (View Lipitor Review and Lipitor Label ), AMBIEN (View Ambien Review and Ambien Label ).

7013388-2 | Acute Graft Versus Host Disease In Skin, Biopsy Liver Abnormal, Hepatic Enzyme Increased
Adverse event was reported on Sep 21, 2010 by a Male patient taking Thymoglobulin (View Usage) (Dosage: Unk) was diagnosed with bone marrow conditioning regimen, prophylaxis against graft versus host disease and. Location: UNITED STATES , child 8 years of age, Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in skin, biopsy liver abnormal, hepatic enzyme increased. During the same period patient was treated with BUSULFAN (View Busulfan Review and Busulfan Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

7013384-5 | Cerebral Haemorrhage, Cytomegalovirus Infection, Liver Disorder
on Sep 16, 2010 Female patient from JAPAN , weighting 127.9 lb, was diagnosed with aplastic anaemia, infection prophylaxis, allergy prophylaxis and was treated with Thymoglobulin (View Usage). Patient had the following side effects: cerebral haemorrhage, cytomegalovirus infection (What is cytomegalovirus infection?), liver disorder. Thymoglobulin dosage: 213 Mg, Qd. During the same period patient was treated with CYCLOSPORINE (Unk) (View Cyclosporine Review and Cyclosporine Label ), SULFAMETHOXAZOLE W (Unk) (View Sulfamethoxazole W Review and Sulfamethoxazole W Label ), METHYLPREDNISOLONE SODIUM SUCCINATE (Unk) (View Methylprednisolone Sodium Succinate Review and Methylprednisolone Sodium Succinate Label ), NEUPOGEN (Unk) (View Neupogen Review and Neupogen Label ).

7013375-4 | Cholecystitis Acute, Depressive Symptom, Pyrexia
on Sep 17, 2010 Female patient from JAPAN , weighting 103.6 lb, was diagnosed with aplastic anaemia, hypertension, antifungal prophylaxis, constipation (What is constipation?), nausea (What is nausea?), tolosa-hunt syndrome, prophylaxis against gastrointestinal ulcer, insomnia and was treated with Thymoglobulin (View Usage). After Thymoglobulin was administered, patient had the following side effects: cholecystitis acute, depressive symptom, pyrexia. Thymoglobulin dosage: 175 Mg, Qd. During the same period patient was treated with AMLODIPINE BESYLATE (Unk) (View Amlodipine Besylate Review and Amlodipine Besylate Label ), VORICONAZOLE (Unk) (View Voriconazole Review and Voriconazole Label ), MAGNESIUM OXIDE (Unk) (View Magnesium Oxide Review and Magnesium Oxide Label ), DOMPERIDONE (Unk) (View Domperidone Review and Domperidone Label ), SENNOSIDE (Unk) (View Sennoside Review and Sennoside Label ), PREDNISOLONE (Unk) (View Prednisolone Review and Prednisolone Label ), LANSOPRAZOLE (Unk) (View Lansoprazole Review and Lansoprazole Label ), ZOPICLONE (Unk) (View Zopiclone Review and Zopiclone Label ). Patient was hospitalized.

7013367-5 | Multi-organ Failure, Pulmonary Haemorrhage, Renal Failure
Patient was taking Thymoglobulin (View Usage). Patient experienced the following unwanted or unexpected effects: multi-organ failure, pulmonary haemorrhage, renal failure on Sep 21, 2010 from UNITED STATES Additional patient health information: Female patient , child 10 years of age, was diagnosed with prophylaxis against transplant rejection, immunosuppression, antifungal prophylaxis and. Thymoglobulin dosage: 1.5 Mg/kg, Unk. During the same period patient was treated with METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), MYCOPHENOLATE MOFETIL (1200 Mg/m2, Qd) (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TRIMETHOPRIM + SULFAMETHOXAZOLE (View Trimethoprim + Sulfamethoxazole Review and Trimethoprim + Sulfamethoxazole Label ).

7012250-9 | Blood Alkaline Phosphatase Increased, Blood Creatinine Increased, Chest Pain, Device Related Infection, Dizziness, Hypokalaemia, Nephritis, Oedema, Palpitations
Adverse event was reported on Sep 15, 2010 by a Female patient taking Thymoglobulin (View Usage) (Dosage: 225 Mg, Qd) was diagnosed with aplastic anaemia, antiviral prophylaxis, antifungal prophylaxis, prophylaxis against gastrointestinal ulcer and. Location: JAPAN , weighting 134.5 lb, Patient had the following side effects: blood alkaline phosphatase increased, blood creatinine increased, chest pain (What is chest pain?), device related infection, dizziness (What is dizziness?), hypokalaemia, nephritis, oedema, palpitations. During the same period patient was treated with VALACYCLOVIR (Unk) (View Valacyclovir Review and Valacyclovir Label ), POLYMYXIN B SULFATE (Unk) (View Polymyxin-b-sulfate Review and Polymyxin-b-sulfate Label ), FLUCONAZOLE (Unk) (View Fluconazole Review and Fluconazole Label ), SULFAMETHOPRIM (Unk) (View Sulfamethoprim Review and Sulfamethoprim Label ), ANTIBIOTICS RESISTANT LACTIC ACID BACTERIAE (Unk) (View Antibiotics-resistant Lactic Acid Bacteriae Review and Antibiotics-resistant Lactic Acid Bacteriae Label ), CYCLOSPORINE (Unk) (View Cyclosporine Review and Cyclosporine Label ), METHYLPREDNISOLONE SODIUM SUCCINATE (Unk) (View Methylprednisolone Sodium Succinate Review and Methylprednisolone Sodium Succinate Label ), LANSOPRAZOLE (Unk) (View Lansoprazole Review and Lansoprazole Label ). Patient was hospitalized.

7009121-0 | Bronchopulmonary Aspergillosis, Epstein-barr Virus Associated Lymphoproliferative Disorder, Fungal Infection, Histiocytosis Haematophagic, Multi-organ Failure
on Sep 15, 2010 Male patient from JAPAN , weighting 125.7 lb, was diagnosed with bone marrow conditioning regimen, prophylaxis and was treated with Thymoglobulin (View Usage). After Thymoglobulin was administered, patient had the following side effects: bronchopulmonary aspergillosis, epstein-barr virus associated lymphoproliferative disorder, fungal infection (What is fungal infection?), histiocytosis haematophagic, multi-organ failure. Thymoglobulin dosage: 70 Mg, Qd. During the same period patient was treated with URSODIOL (Unk) (View Ursodiol Review and Ursodiol Label ), CIPROFLOXACIN HYDROCHLORIDE (Unk) (View Ciprofloxacin Hydrochloride Review and Ciprofloxacin Hydrochloride Label ), ACICLOVIR (Unk) (View Aciclovir Review and Aciclovir Label ), LOXOPROFEN SODIUM (Unk) (View Loxoprofen Sodium Review and Loxoprofen Sodium Label ), AMPHOTERICIN B (Unk) (View Amphotericin B Review and Amphotericin B Label ), ITRACONAZOLE (Unk) (View Itraconazole Review and Itraconazole Label ). Patient was hospitalized.

7006025-4 | Febrile Neutropenia, Pruritus, Pyrexia, Stomatitis
on Sep 10, 2010 Female patient from JAPAN , weighting 81.57 lb, was diagnosed with aplastic anaemia and was treated with Thymoglobulin (View Usage). Patient experienced the following unwanted or unexpected effects: febrile neutropenia, pruritus, pyrexia, stomatitis. Thymoglobulin dosage: 25 Mg, Qd. During the same period patient was treated with METHYLPREDNISOLONE SODIUM SUCCINATE (Unk) (View Methylprednisolone Sodium Succinate Review and Methylprednisolone Sodium Succinate Label ), CYCLOSPORINE (Unk) (View Cyclosporine Review and Cyclosporine Label ). Patient was hospitalized.

7006021-7 |
Patient was taking Thymoglobulin (View Usage). on Sep 08, 2010 from JAPAN Additional patient health information: Male patient , 52 years of age, was diagnosed with bone marrow conditioning regimen and. Thymoglobulin dosage: 2.5 Mg/kg, Qd.

7005993-4 | Cerebral Haemorrhage, Histiocytosis Haematophagic
Adverse event was reported on Sep 09, 2010 by a Male patient taking Thymoglobulin (View Usage) (Dosage: 175 Mg, Qd) was diagnosed with histiocytosis haematophagic, disseminated intravascular coagulation and. Location: JAPAN , weighting 110.2 lb, After Thymoglobulin was administered, patient had the following side effects: cerebral haemorrhage, histiocytosis haematophagic. During the same period patient was treated with GABEXATE MESILATE (Unk) (View Gabexate Mesilate Review and Gabexate Mesilate Label ), BIAPENEM (View Biapenem Review and Biapenem Label ), METHYLPREDNISOLONE SODIUM SUCCINATE (View Methylprednisolone Sodium Succinate Review and Methylprednisolone Sodium Succinate Label ), MICAFUNGIN SODIUM (View Micafungin Sodium Review and Micafungin Sodium Label ).

7000614-9 | Cytomegalovirus Test Positive, Epstein-barr Virus Associated Lymphoproliferative Disorder, Febrile Neutropenia
on Sep 15, 2010 Male patient from JAPAN , weighting 85.98 lb, was diagnosed with bone marrow conditioning regimen, antifungal prophylaxis and was treated with Thymoglobulin (View Usage). Patient experienced the following unwanted or unexpected effects: cytomegalovirus test positive, epstein-barr virus associated lymphoproliferative disorder, febrile neutropenia. Thymoglobulin dosage: 50 Mg, Qd. During the same period patient was treated with SULFAMETOXAZOL (Unk) (View Sulfametoxazol Review and Sulfametoxazol Label ), URSODIOL (Unk) (View Ursodiol Review and Ursodiol Label ), SPARFLOXACIN (Unk) (View Sparfloxacin Review and Sparfloxacin Label ), ACYCLOVIR SODIUM (Unk) (View Acyclovir Sodium Review and Acyclovir Sodium Label ), DANAPAROID SODIUM (Unk) (View Danaparoid Sodium Review and Danaparoid Sodium Label ), METHYLPREDNISOLONE SODIUM SUCCINATE (Unk) (View Methylprednisolone Sodium Succinate Review and Methylprednisolone Sodium Succinate Label ), HYDROXYZINE PAMOATE (Unk) (View Hydroxyzine Pamoate Review and Hydroxyzine Pamoate Label ), MICAFUNGIN SODIUM (Unk) (View Micafungin Sodium Review and Micafungin Sodium Label ).

6999444-3 |
on Sep 08, 2010 Male patient from JAPAN , 52 years of age, was diagnosed with bone marrow conditioning regimen and was treated with Thymoglobulin (View Usage). . Thymoglobulin dosage: 2.5 Mg/kg, Qd.

6998354-5 | Cerebral Infarction, Febrile Neutropenia, Pyrexia, Therapeutic Response Decreased
Patient was taking Thymoglobulin (View Usage). After Thymoglobulin was administered, patient had the following side effects: cerebral infarction, febrile neutropenia, pyrexia, therapeutic response decreased on Sep 10, 2010 from JAPAN Additional patient health information: Female patient , weighting 30.86 lb, was diagnosed with aplastic anaemia, prophylaxis and. Thymoglobulin dosage: 50 Mg, Qd. During the same period patient was treated with METHYLPREDNISOLONE SODIUM SUCCINATE (Unk) (View Methylprednisolone Sodium Succinate Review and Methylprednisolone Sodium Succinate Label ), CYCLOSPORINE (Unk) (View Cyclosporine Review and Cyclosporine Label ), NEUPOGEN (Unk) (View Neupogen Review and Neupogen Label ), LENOGRASTIM (Unk) (View Lenograstim Review and Lenograstim Label ), NARTOGRASTIM (Unk) (View Nartograstim Review and Nartograstim Label ), ACYCLOVIR SODIUM (Unk) (View Acyclovir Sodium Review and Acyclovir Sodium Label ). Patient was hospitalized and became disabled.

6998189-3 | Cardiac Failure, Herpes Zoster
Adverse event was reported on Sep 10, 2010 by a Female patient taking Thymoglobulin (View Usage) (Dosage: 3.75 Mg/kg, Qd) was diagnosed with aplastic anaemia and. Location: JAPAN , weighting 85.98 lb, Patient experienced the following unwanted or unexpected effects: cardiac failure, herpes zoster. During the same period patient was treated with CYCLOSPORINE (Unk) (View Cyclosporine Review and Cyclosporine Label ), CARBAZOCHROME SODIUM SULFONATE (90 Mg, Qd) (View Carbazochrome Sodium Sulfonate Review and Carbazochrome Sodium Sulfonate Label ), FAMOTIDINE (20 Mg, Qd) (View Famotidine Review and Famotidine Label ).

6991986-X | Blood Creatinine Increased, Therapeutic Response Decreased, Transplant Rejection
on Sep 08, 2010 Male patient from INDIA , 27 years of age, weighting 137.8 lb, was diagnosed with prophylaxis against transplant rejection and was treated with Thymoglobulin (View Usage). Patient had the following side effects: blood creatinine increased, therapeutic response decreased, transplant rejection. Thymoglobulin dosage: 3 Mg, Once. During the same period patient was treated with CYCLOSPORINE (150 Mg, Bid) (View Cyclosporine Review and Cyclosporine Label ), WYSOLONE (20 Mg, Unk) (View Wysolone Review and Wysolone Label ), CELLCEPT (500 Mg, Bid) (View Cellcept Review and Cellcept Label ).

6973997-3 | Anaphylactic Reaction, Haemolytic Anaemia
on Sep 08, 2010 Male patient from SINGAPORE , 18 years of age, was treated with Thymoglobulin (View Usage). After Thymoglobulin was administered, patient had the following side effects: anaphylactic reaction, haemolytic anaemia. Thymoglobulin dosage: .

6972867-4 | Anaemia, Circulatory Collapse, Epstein-barr Virus Associated Lymphoproliferative Disorder, Haemorrhage, Hepatic Function Abnormal, Histiocytosis Haematophagic, Hyperammonaemia, Hyperuricaemia, Hypoalbuminaemia
Patient was taking Thymoglobulin (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, circulatory collapse, epstein-barr virus associated lymphoproliferative disorder, haemorrhage, hepatic function abnormal, histiocytosis haematophagic, hyperammonaemia, hyperuricaemia, hypoalbuminaemia on Sep 03, 2010 from JAPAN Additional patient health information: Female patient , weighting 30.86 lb, was diagnosed with bone marrow conditioning regimen, infection prophylaxis and. Thymoglobulin dosage: 35 Mg, Qd. During the same period patient was treated with FLUDARABINE PHOSPHATE (Unk) (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), MELPHALAN (Unk) (View Melphalan Review and Melphalan Label ), PIPERACILLIN SODIUM (Unk) (View Piperacillin Sodium Review and Piperacillin Sodium Label ), MICAFUNGIN SODIUM (Unk) (View Micafungin Sodium Review and Micafungin Sodium Label ), CEFTRIAXONE SODIUM (Unk) (View Ceftriaxone Sodium Review and Ceftriaxone Sodium Label ), IMMUNE GLOBULIN INTRAVENOUS (HUMAN) (Unk) (View Immune Globulin Intravenous (human) Review and Immune Globulin Intravenous (human) Label ), VANCOMYCIN HCL (Unk) (View Vancomycin Hcl Review and Vancomycin Hcl Label ), POLYMYXIN B SULFATE (Unk) (View Polymyxin-b-sulfate Review and Polymyxin-b-sulfate Label ).

6971598-4 | Aspergillus Test, Fluid Overload, Hyperbilirubinaemia, Hypotension, Hypoxia, Multi-organ Failure
Adverse event was reported on Sep 02, 2010 by a Male patient taking Thymoglobulin (View Usage) (Dosage: Unk) was diagnosed with bone marrow conditioning regimen, non-hodgkin's lymphoma and. Location: UNITED STATES , 64 years of age, Patient had the following side effects: aspergillus test, fluid overload, hyperbilirubinaemia, hypotension, hypoxia, multi-organ failure. During the same period patient was treated with CLOFARABINE (40 Mg/m2, Qd) (View Clofarabine Review and Clofarabine Label ), NIFEDIPINE (View Nifedipine Review and Nifedipine Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), MEROPENEM (Unk) (View Meropenem Review and Meropenem Label ), VANCOMYCIN (View Vancomycin Review and Vancomycin Label ). Patient was hospitalized.

6971594-7 | Acute Myocardial Infarction, Fluid Overload, Mucosal Inflammation, Pneumonia, Renal Failure, Respiratory Failure, Septic Shock, Venoocclusive Disease
on Aug 31, 2010 Female patient from UNITED STATES , 31 years of age, was diagnosed with bone marrow conditioning regimen, acute myeloid leukaemia, haematopoietic stem cell mobilisation and was treated with Thymoglobulin (View Usage). After Thymoglobulin was administered, patient had the following side effects: acute myocardial infarction, fluid overload, mucosal inflammation, pneumonia (What is pneumonia?), renal failure, respiratory failure, septic shock, venoocclusive disease. Thymoglobulin dosage: 35 Mg, Qd. During the same period patient was treated with NEUPOGEN (600 Mcg, Qd) (View Neupogen Review and Neupogen Label ), MOZOBIL (16584 Mcg, Qd) (View Mozobil Review and Mozobil Label ), FLUDARABINE (72 Mg, Qd) (View Fludarabine Review and Fludarabine Label ), BUSULFAN (234 Mg, Qd) (View Busulfan Review and Busulfan Label ), ACETAMINOPHEN (325 Mg, Q4hr) (View Acetaminophen Review and Acetaminophen Label ). Patient was hospitalized.

6971198-6 | Aplastic Anaemia, Haemorrhage, Therapeutic Response Decreased
on Sep 02, 2010 Female patient from JAPAN , 71 years of age, weighting 125.7 lb, was diagnosed with aplastic anaemia and was treated with Thymoglobulin (View Usage). Patient experienced the following unwanted or unexpected effects: aplastic anaemia, haemorrhage, therapeutic response decreased. Thymoglobulin dosage: Unk.

6970564-2 | Gout, Viraemia
Patient was taking Thymoglobulin (View Usage). Patient had the following side effects: gout (What is gout?), viraemia on Sep 02, 2010 from UNITED STATES Additional patient health information: Female patient , 69 years of age, was diagnosed with prophylaxis against transplant rejection and. Thymoglobulin dosage: 1.5 Mg/kg, Qd. During the same period patient was treated with TACROLIMUS (Unk) (View Tacrolimus Review and Tacrolimus Label ), MYFORTIC (1440 Mg, Qd) (View Myfortic Review and Myfortic Label ), PREDNISONE (10 Mg, Qd) (View Prednisone Review and Prednisone Label ).